https://www.nytimes.com/2021/04/22/us/politics/johnson-and-johnson-vaccine.html
The committee is scheduled to meet on Friday to discuss whether to recommend lifting, extending or modifying the pause that was initiated on April 13.
............
Even if the C.D.C.’s advisory committee decides on Friday that the benefits of Johnson & Johnson’s single-dose vaccine outweigh its risks, the company will still face manufacturing hurdles at a Baltimore plant that regulators have so far refused to certify. That plant was supposed to deliver the bulk of the nearly 100 million doses Johnson & Johnson had promised to have ready by the end of May.
